Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
The Transmitter’s most-read neuroscience book excerpts of 2025
Books by Nachum Ulanovsky, Nicole Rust, and Andrew Iwaniuk and Georg Striedter made the list of some of the year's most engaging neuroscience titles.
The Transmitter’s most-read neuroscience book excerpts of 2025
Books by Nachum Ulanovsky, Nicole Rust, and Andrew Iwaniuk and Georg Striedter made the list of some of the year's most engaging neuroscience titles.
Neuroscience’s leaders, legacies and rising stars of 2025
Here are seven stories from the past year about some of the field’s most engaging figures.
Neuroscience’s leaders, legacies and rising stars of 2025
Here are seven stories from the past year about some of the field’s most engaging figures.
The Transmitter’s top news articles of 2025
Check out some of our most-read stories, covering neuroscience funding and policy changes in the United States, and methodological issues in high-profile neuroscience papers.
The Transmitter’s top news articles of 2025
Check out some of our most-read stories, covering neuroscience funding and policy changes in the United States, and methodological issues in high-profile neuroscience papers.